A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-23. Anything still debated is marked as such rather than presented as settled.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
M. Marcu-Pipeline conveyors(pneumatic wheeled pipeline conveyors-state of the art/photos-1990) at page 45 in the "Material handling in pyrometallurgy": proceedings of the International Symposium on Materials Handling in Pyrometallurgy, Hamilton, Ontario, August 26–30, 1990 Twigge-Molecey, T. Price, Metallurgical Society of CIM. Non-Ferrous Pyrometallurgy Section Pergamon Press, Sep 30, 1990 - Technology & Engineering - 227 pages
Amyloidoses can be considered protein misfolding diseases. The vast majority of proteins that have been found to form amyloid deposits are secreted proteins, so the misfolding and formation of amyloid occurs outside cells, in the extracellular space. Of the 37 proteins so far identified as being vulnerable to amyloid formation, only four are cytosolic. Most amyloid-forming proteins are relatively small, but otherwise there is currently no evidence of structural or functional similarities among proteins known to form disease-associated amyloids. One third of amyloid disease is hereditary, in which case there is normally an early age of onset. Half of amyloid-related diseases are sporadic and have a late age of onset – in these cases, the protein aggregation may be associated with aging-related decline in protein regulation. Some medical treatments are associated with amyloid disease, but this is rare. Amyloid-forming proteins aggregate into distinctive fibrillar forms with a beta-sheet structure. The beta-sheet form of amyloid is proteolysis-resistant, meaning it can not be degraded or broken down. As a result, amyloid deposits into the body's extracellular space. The process of forming amyloid fibrils is thought to have intermediate oligomeric forms. Both the oligomers and amyloid fibrils can be toxic to cells and can interfere with proper organ function. The relative significance of different aggregation species may depend on the protein involved and the organ system affected.
Soft tissues have the potential to undergo large deformations and still return to the initial configuration when unloaded, i.e. they are hyperelastic materials, and their stress-strain curve is nonlinear. The soft tissues are also viscoelastic, incompressible and usually anisotropic. Some viscoelastic properties observable in soft tissues are: relaxation, creep and hysteresis. In order to describe the mechanical response of soft tissues, several methods have been used. These methods include: hyperelastic macroscopic models based on strain energy, mathematical fits where nonlinear constitutive equations are used, and structurally based models where the response of a linear elastic material is modified by its geometric characteristics.
=== Psychomotor effects === The most common effect is fatigue or somnolence, particularly in older adults, although patients with pre-existing daytime sleepiness and fatigue may experience paradoxical improvement of these symptoms. Escitalopram has not been shown to affect serial reaction time, logical reasoning, serial subtraction, multitasking, or Mackworth Clock task performance.
Sources: en.wikipedia.org
== Cambridge Dictionary == The Cambridge Dictionary Word of the Year, by Cambridge University Press & Assessment, has been published every year since 2015. The word is chosen based on "user data, zeitgeist, and language." In 2024, Cambridge picked "manifest" as its Word of the Year. Traditionally, the word has been used as an adjective meaning "obvious", or as a verb meaning "to show something clearly through signs or actions". The word was chosen owing to its use by celebrities, particularly on social media, as a verb meaning "to imagine achieving something you want, in the belief doing so will make it more likely to happen".
=== Signs and symptoms === Riboflavin deficiency (also called ariboflavinosis) results in stomatitis, symptoms of which include chapped and fissured lips, inflammation of the corners of the mouth (angular stomatitis), sore throat, painful red tongue, and hair loss. The eyes can become itchy, watery, bloodshot, and sensitive to light. Riboflavin deficiency is associated with anemia. Prolonged riboflavin insufficiency may cause degeneration of the liver and nervous system. Riboflavin deficiency may increase the risk of preeclampsia in pregnant women. Deficiency of riboflavin during pregnancy can result in fetal birth defects, including heart and limb deformities.
Defending against a full Russian or Chinese attack would require hundreds of thousands of satellites," according to MIT physicists Lisbeth Gronlund and David Wright. The cost of launching satellites is expected to decrease when the heavy-lift SpaceX Starship launch vehicle enters service. Still, the extreme expense of creating such a constellation—and replacing satellites as their orbits decay—has led the U.S. military to also pursue space-based midcourse options that would require fewer satellites. But these would be more expensive and no better than ground-based interceptors at telling decoys from warheads. Space-based interceptors would be guided by the nascent Hypersonic and Ballistic Tracking Space Sensor system, one of the tracking elements of the Space Development Agency's (SDA) seven-layer Proliferated Warfighter Space Architecture (PWSA). The Golden Dome would also be aimed at detecting and countering strikes delivered from a fractional orbital bombardment system (FOBS). Pentagon leaders have said the system could be used to put offensive weapons in space, giving a global strike capability that would create offensive overmatch. Defense Secretary Pete Hegseth has said the U.S. "will be able to strike anywhere, anytime". Satellites might carry the bunker-busting Common-Hypersonic Glide Body (C-HGB), which can reportedly fly 1,000 miles to strike within 14 inches of its target. The missile was designed to fit the HIMARS ground launcher, so several can be compactly racked in a satellite payload bays.
When placed in a nonchiral solvent like water, D-peptides, as well as the larger polypeptide D-proteins, have similar but mirrored properties to the L-peptides and L-proteins with identical sequences. If an L-protein does not require a chaperone or a structural cofactor to fold, its D-enantiomer protein should have a mirror image conformation with respect to the L-protein (Figure 2). A D-enzyme should act on substrates of reverse chirality compared to the L-enzyme with the same sequence. Similarly, if an L-peptide binds to an L-protein, their D-peptide and D-protein counterparts should bind together in a mirrored way. D-peptides also have properties that make them attractive as drugs. D-peptides are less susceptible to be degraded in the stomach or inside cells by proteolysis. D-peptide drugs can, therefore, be taken orally and are effective for a longer period of time. D-peptides are easy to synthesize when compared to many other drugs. In some cases, D-peptides can have a low immunogenic response.
==== Elimination ==== Instead of by hepatic metabolism, atenolol is eliminated from the blood mainly via renal excretion. Atenolol is excreted about 40 to 50% in urine and 50% in feces with oral administration. Conversely, it is excreted 85 to 100% in urine unchanged and 10% in feces with intravenous administration. Only very small amounts of hydroxyatenolol and atenolol glucuronide are found in urine with atenolol. The elimination half-life of atenolol is about 6 to 7 hours. The half-life of atenolol does not change with continuous administration. With intravenous administration, atenolol levels rapidly decline (5- to 10-fold) during the first 7 hours and thereafter decline at a rate similar to that with oral administration. The elimination of atenolol is slowed in renal impairment, with the elimination rate being closely related to the glomerular filtration rate (GFR) and with significant accumulation occurring when the creatinine clearance rate is under 35 mL/min/1.73 m2. At a GFR of less than 10 mL/min, the half-life of atenolol increases up to 36 hours.
Sources: en.wikipedia.org
Food preservation includes processes that make food more resistant to microorganism growth and slow the oxidation of fats. This slows down the decomposition and rancidification process. Food preservation may also include processes that inhibit visual deterioration, such as the enzymatic browning reaction in apples after they are cut during food preparation. By preserving food, food waste can be reduced, which is an important way to decrease production costs and increase the efficiency of food systems, improve food security and nutrition and contribute towards environmental sustainability. For instance, it can reduce the environmental impact of food production. Many processes designed to preserve food involve more than one food preservation method. Preserving fruit by turning it into jam, for example, involves boiling (to reduce the fruit's moisture content and to kill bacteria, etc.), sugaring (to prevent their re-growth) and sealing within an airtight jar (to prevent recontamination). Different food preservation methods have different impacts on the quality of the food and food systems. Some traditional methods of preserving food have been shown to have a lower energy input and carbon footprint compared to modern methods. Some methods of food preservation are also known to create carcinogens.
== Impact on materials == When a book or paper becomes moldy, the fungi will digest its food source, paper and cloth (such as book covers and bindings) in order to survive. This process stains and destroys books, papers, and other library collections over time. During their growth mold and mildew produce citric, gluconic, oxalic, or other organic acids that can damage paper, leather, cloth, etc. They also at times produce color bodies, leading to staining which is difficult to remove. Mold will continually grow until it uses up its food source, which means a library collection could be totally consumed. Unless every mold spore is treated, the issue will just return. Mold's enduring nature makes treatment difficult and prevention all the more necessary.
== Overdose == There have been cases of death with dimethyltryptamine (DMT). In terms of extrapolated human lethal dose based on animal studies and human case reports, the lethal dose of ayahuasca relative to a typical recreational or entheogenic dose is estimated to be 50-fold.
==== Thymomas ==== Tumours originating from the thymic epithelial cells are called thymomas. They most often occur in adults older than 40. Tumours are generally detected when they cause symptoms, such as a neck mass or affecting nearby structures such as the superior vena cava; detected because of screening in patients with myasthenia gravis, which has a strong association with thymomas and hyperplasia; and detected as an incidental finding on imaging such as chest X-rays. Hyperplasia and tumours originating from the thymus are associated with other autoimmune diseases – such as hypogammaglobulinemia, Graves disease, pure red cell aplasia, pernicious anaemia and dermatomyositis, likely because of defects in negative selection in proliferating T cells. Thymomas can be benign; benign but by virtue of expansion, invading beyond the capsule of the thymus ("invasive thymoma"), or malignant (a carcinoma). This classification is based on the appearance of the cells. A WHO classification also exists but is not used as part of standard clinical practice. Benign tumours confined to the thymus are most common, followed by locally invasive tumours, and then by carcinomas. There is variation in reporting, with some sources reporting malignant tumours as more common. Invasive tumours, although not technically malignant, can still spread (metastasise) to other areas of the body. Even though thymomas originate from epithelial cells, they can also contain thymocytes. Treatment of thymomas often requires surgery to remove the entire thymus.
=== Pharmacokinetics === Absorption Dapoxetine is a white, powdery, water-insoluble substance. Taken one to three hours before sexual activity, it is rapidly absorbed in the body. Its maximum plasma concentration (Cmax) is reached one to two hours after oral administration. The Cmax and AUC (area under the plasma vs. time curve) is dose dependent. The Cmax and Tm (time needed to obtain the maximum plasma concentration) after single doses of dapoxetine 30 mg and 60 mg are 297 and 498 ng/ml at 1.01 and 1.27 hours, respectively. A high-fat meal does reduce the Cmax slightly, but it is insignificant. In fact, food does not alter dapoxetine pharmacokinetics. It can be taken with or without food.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.